CN102834100A - 新型pan-CDK抑制剂用于治疗肿瘤的用途 - Google Patents

新型pan-CDK抑制剂用于治疗肿瘤的用途 Download PDF

Info

Publication number
CN102834100A
CN102834100A CN2011800166124A CN201180016612A CN102834100A CN 102834100 A CN102834100 A CN 102834100A CN 2011800166124 A CN2011800166124 A CN 2011800166124A CN 201180016612 A CN201180016612 A CN 201180016612A CN 102834100 A CN102834100 A CN 102834100A
Authority
CN
China
Prior art keywords
amino
methyl
trifluoromethyl
phenyl
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800166124A
Other languages
English (en)
Chinese (zh)
Inventor
U·吕金
G·西迈斯特
A·M·温内尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN102834100A publication Critical patent/CN102834100A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2011800166124A 2010-04-01 2011-03-28 新型pan-CDK抑制剂用于治疗肿瘤的用途 Pending CN102834100A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102010014426A DE102010014426A1 (de) 2010-04-01 2010-04-01 Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010014426.6 2010-04-01
PCT/EP2011/054733 WO2011120922A1 (de) 2010-04-01 2011-03-28 Verwendung neuer pan-cdk-inhibitoren zur behandlung von tumoren

Publications (1)

Publication Number Publication Date
CN102834100A true CN102834100A (zh) 2012-12-19

Family

ID=43858236

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800166124A Pending CN102834100A (zh) 2010-04-01 2011-03-28 新型pan-CDK抑制剂用于治疗肿瘤的用途

Country Status (21)

Country Link
US (1) US20130210846A1 (enExample)
EP (1) EP2552450A1 (enExample)
JP (1) JP5816259B2 (enExample)
KR (1) KR20130014678A (enExample)
CN (1) CN102834100A (enExample)
AU (1) AU2011234654B2 (enExample)
BR (1) BR112012024422A2 (enExample)
CA (1) CA2794996A1 (enExample)
CL (1) CL2012002753A1 (enExample)
CR (1) CR20120502A (enExample)
DE (1) DE102010014426A1 (enExample)
DO (1) DOP2012000260A (enExample)
EC (1) ECSP12012198A (enExample)
MA (1) MA34098B1 (enExample)
MX (1) MX337722B (enExample)
NZ (1) NZ602710A (enExample)
PH (1) PH12012501945A1 (enExample)
SG (2) SG10201502566SA (enExample)
TN (1) TN2012000469A1 (enExample)
UA (1) UA108494C2 (enExample)
WO (1) WO2011120922A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105007945A (zh) * 2013-03-07 2015-10-28 拜耳医药股份有限公司 (rs)-s-环丙基-s-(4-{[4-{[(1r,2r)-2-羟基-1-甲基丙基]氧基}-5-(三氟甲基)嘧啶-2-基]氨基}苯基)亚砜亚胺用于治疗特定肿瘤的用途
CN105530937A (zh) * 2013-03-13 2016-04-27 昂克希尔迪克斯有限公司 使用7-苄基-10-(2-甲基苄基)-2,6,7,8,9,10-六氢咪唑并[1,2-a]吡啶并[4,3-d]嘧啶-5(3h)-酮的联合疗法
CN116528869A (zh) * 2020-11-27 2023-08-01 安锐生物医药科技(广州)有限公司 氨基杂芳基激酶抑制剂

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013234451A1 (en) * 2012-03-21 2014-09-25 Bayer Intellectual Property Gmbh Use of (RS)-S-cyclopropyl-S-(4-{[4-{[1R, 2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl] amino}phenyl)sulfoximide for treating specific tumours
WO2014173815A1 (en) * 2013-04-23 2014-10-30 Bayer Pharma Aktiengesellschaft Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours
US20160151370A1 (en) * 2013-06-21 2016-06-02 Bayer Pharma Aktiengesellschaft Substituted Benzylpyrazoles
WO2015071231A1 (de) * 2013-11-14 2015-05-21 Bayer Pharma Aktiengesellschaft Kombinationen von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung von tumoren
CN109283263B (zh) * 2017-07-21 2019-06-25 南京正大天晴制药有限公司 用于雷替曲塞合成质量控制的检测分析方法
CN109283279B (zh) * 2017-07-21 2019-11-01 南京正大天晴制药有限公司 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1867553A (zh) * 2003-10-16 2006-11-22 舍林股份公司 作为cdk 和/或vegf 抑制剂的氨基亚砜取代的嘧啶化合物、其制备方法以及作为药物的用途
CN101679310A (zh) * 2007-06-20 2010-03-24 拜耳先灵医药股份有限公司 作为Tie2激酶抑制剂的炔基嘧啶

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
WO1999002162A1 (en) 1997-07-12 1999-01-21 Cancer Research Campaign Technology Limited Cyclin dependent kinase inhibiting purine derivatives
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
AU5438499A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
EP1392662B1 (de) 2001-05-29 2009-01-07 Bayer Schering Pharma Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
EP1483260A1 (de) 2002-03-11 2004-12-08 Schering Aktiengesellschaft Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
DE102006027156A1 (de) * 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
EP1878726A1 (en) * 2006-07-12 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Substituted sulphoximines as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising the same, methods of preparing the same and uses of the same
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP2179991A1 (de) 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1867553A (zh) * 2003-10-16 2006-11-22 舍林股份公司 作为cdk 和/或vegf 抑制剂的氨基亚砜取代的嘧啶化合物、其制备方法以及作为药物的用途
CN101679310A (zh) * 2007-06-20 2010-03-24 拜耳先灵医药股份有限公司 作为Tie2激酶抑制剂的炔基嘧啶

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105007945A (zh) * 2013-03-07 2015-10-28 拜耳医药股份有限公司 (rs)-s-环丙基-s-(4-{[4-{[(1r,2r)-2-羟基-1-甲基丙基]氧基}-5-(三氟甲基)嘧啶-2-基]氨基}苯基)亚砜亚胺用于治疗特定肿瘤的用途
CN105530937A (zh) * 2013-03-13 2016-04-27 昂克希尔迪克斯有限公司 使用7-苄基-10-(2-甲基苄基)-2,6,7,8,9,10-六氢咪唑并[1,2-a]吡啶并[4,3-d]嘧啶-5(3h)-酮的联合疗法
CN116528869A (zh) * 2020-11-27 2023-08-01 安锐生物医药科技(广州)有限公司 氨基杂芳基激酶抑制剂

Also Published As

Publication number Publication date
CR20120502A (es) 2012-11-20
WO2011120922A1 (de) 2011-10-06
SG10201502566SA (en) 2015-05-28
PH12012501945A1 (en) 2017-08-09
UA108494C2 (uk) 2015-05-12
US20130210846A1 (en) 2013-08-15
EP2552450A1 (de) 2013-02-06
AU2011234654B2 (en) 2015-08-06
MX337722B (es) 2016-03-16
DE102010014426A1 (de) 2011-10-06
CA2794996A1 (en) 2011-10-06
DOP2012000260A (es) 2013-03-31
AU2011234654A1 (en) 2012-10-25
SG183925A1 (en) 2012-10-30
JP5816259B2 (ja) 2015-11-18
ECSP12012198A (es) 2012-10-30
BR112012024422A2 (pt) 2016-05-31
NZ602710A (en) 2014-05-30
KR20130014678A (ko) 2013-02-08
JP2013523680A (ja) 2013-06-17
TN2012000469A1 (en) 2014-01-30
MX2012011427A (es) 2013-03-05
CL2012002753A1 (es) 2013-01-18
MA34098B1 (fr) 2013-03-05

Similar Documents

Publication Publication Date Title
TWI549954B (zh) 經取代之２，３－二氫咪唑并［１，２－ｃ］喹唑啉鹽
CN102834100A (zh) 新型pan-CDK抑制剂用于治疗肿瘤的用途
TW201211049A (en) Substituted imidazopyridazines
CN103958515A (zh) 氨基取代的咪唑并哒嗪
TW201245194A (en) Triazolopyridines
JP2014510118A (ja) 置換イミダゾピリジン類およびその中間体
DE102010014427A1 (de) Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
AU2013234451A1 (en) Use of (RS)-S-cyclopropyl-S-(4-{[4-{[1R, 2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl] amino}phenyl)sulfoximide for treating specific tumours
HK1179529A (en) Use of novel pan-cdk inhibitors for treating tumors
WO2014173815A1 (en) Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5- (trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for the treatment of specific tumours
US20160045496A1 (en) Use of (rs)-s-cyclopropyl-s-(4--5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treatment of specific tumours
WO2015071231A1 (de) Kombinationen von (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluormethyl)pyrimidin-2-yl]amino}phenyl)sulfoximid zur behandlung von tumoren

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1179529

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20121219

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1179529

Country of ref document: HK